Navigation Links
DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3
Date:1/28/2011

RALEIGH, N.C., Jan. 28, 2011 /PRNewswire/ -- DARA BioSciences, Inc. (NasdaqCM: DARA), a biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies, announced today that Richard Franco, CEO, will present at RetailInvestorConfrences.com.DATE:

February 3, 2011TIME:

5:00 PM ESTLINK:

www.retailinvestorconferences.comThis will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live, an archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About DARA BioSciences, Inc.DARA BioSciences, Inc. is a Raleigh, North Carolina based biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies.  Presently DARA has two drug candidates with cleared IND (Investigational New Drug) Applications from the United States FDA.  The Company has a pipeline of diverse drug candidates at various stages of development, with 82 granted patents and 56 pending applications (US and foreign).  The first drug candidate KRN5500 has successfully completed a Phase 2 clinical trial treating neuropathic pain in patients with cancer.  KRN5500 met its primary endpoint and was statistically significantly (p=0.03) better than placebo.  A second Phase 2 clinical trial is planned during the first half of 2011.  The second drug candidate DB959 is a highly selective, non-thiazolidinedione (TZD), first-in-class dual PPAR (peroxisome proliferator activat
'/>"/>

SOURCE DARA BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Frontage Laboratories, Inc., a ... US and China, and Spaulding Clinical Research, LLC, a ... Medical Device Manufacturer have entered into a strategic partnership ... footprint by combining Frontage,s presence in China and its ...
... SPRING, Md., Sept. 12, 2011 Today, the U.S. ... office responsible for reviewing all drug and biologic applications ... Research,s (CDER) Office of Oncology Drug Products has been ... Products (OHOP). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) ...
Cached Medicine Technology:Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc. 2Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc. 3FDA Announces Changes in Drug Center's Oncology Office 2FDA Announces Changes in Drug Center's Oncology Office 3
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... been found to reduce the risk of cellular ... top of standard immunosuppression. ,The drug, a ... receptor, thereby inhibiting T-cell proliferation. ,Patients who ... daclizumab or a placebo. ,The primary endpoint ...
... severe depression 'Transcranial Magnetic Stimulation' (TMS) maybe the ... the more aggressive electro-shock therapy., ,Electro-Shock Therapy or ... resort to treat severe depression for many decades. However, ... after therapy and requires general anesthesia. In ECT the ...
... people in the United States, Europe and Japan and many ... drinking calcium water may help in reducing osteoporosis., ,Calcium ... the people do not consume enough of this nutrient. ... osteoporosis but for many teenagers, and those in their twenties ...
... 598 068 nuclear industry workers from 15 countries.// The ... after administrating low doses of radiation. ,This study ... risk among radiation workers in the nuclear industry to ... dose exposure of radiation. ,The study recruits were ...
... time may be putting their health more at risk than ... that feeing angry for a very long time may cause ... pick up habits like smoking and drinking, or inducing stress ... of the literature that had tried to relate to various ...
... suffering from congenital central hypoventilation syndrome (CCHS) may suffer ... ,Congenital Central Hypoventilation Syndrome is the absence ... time. Children suffering from CCHS may not breathe regularly ... may be able to breathe during wakeful hours but ...
Cached Medicine News:Health News:Strong Magnetic Stimulation Can Help Treating Severe Depression 2Health News:Cancer risk among nuclear industry workers 2
Adhesive tape sheets for sealing multiwell plates and blocks;...
Microwell Plate Accessories...
DMSO-resistant microplate sealing film...
Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
Medicine Products: